BackZynerba Pharmaceuticals Overview

Zynerba Pharmaceuticals Net Tangible Assets

Track Zynerba Pharmaceuticals's net tangible assets ($29M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$29.02M
↓ 49.30% YoYΔ $-28.22M vs prior year quarter

Peer trimmed avg / median

Loading

Zynerba Pharmaceuticals Net Tangible Assets History

Loading

Zynerba Pharmaceuticals vs. peers: Net Tangible Assets Comparison

Loading

Zynerba Pharmaceuticals Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Zynerba Pharmaceuticals (ZYNE) FAQ

As of the most recent data (June 2023), ZYNE shows a net tangible assets of $29M. That compares with $57M in the prior-year period — down 49.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZYNE's net tangible assets is now $29M (was $57M) — a 49.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Zynerba Pharmaceuticals is outperforming or lagging.

Tracking ZYNE's net tangible assets over time shows whether Zynerba Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $29M That compares with $57M in the prior-year period — down 49.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Zynerba Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $29M) with ownership activity and broader fundamentals.

Zynerba Pharmaceuticals's net tangible assets is $29M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.